Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Kane Biotech Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by CurlyMickon Jul 22, 2014 12:19pm
113 Views
Post# 22770000

RE:RE:RE:RE: RE:RE:RE:RE:RE:Great news from HC

RE:RE:RE:RE: RE:RE:RE:RE:RE:Great news from HC
NobodyKnowsOne wrote:
CurlyMick wrote: Yes...the toothpaste and oral care products using DispersinB were some of the many fantastic potential game changers in general healthcare that we heard about over the past many years. Maybe we will finally be rewarded for our patience. GLTA

 

Wait,  wasn't the toothpaste to come from the StrixNB formulation?




Could be. We discussed the attack on biofilms as being the key...and I may have wrongly assumed that similar science went into formulating both the topical products and oral ones. Not the first time I'd be mistaken.

The efficacy of StrixNB has been proven for pets...and is safe for them...so maybe we are even closer than I thought for toothpaste for humans. 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities